Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multi-center, Phase II trial studying the combination of mocetinostat and gemcitabine in patients who have previously demonstrated disease progression either while, or within six months after, receiving chemotherapy with a gemcitabine-based regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02303262
Study type Interventional
Source Sarcoma Alliance for Research through Collaboration
Contact
Status Completed
Phase Phase 2
Start date November 12, 2015
Completion date December 2016

See also
  Status Clinical Trial Phase
Terminated NCT03670069 - Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Phase 1
Terminated NCT03074318 - Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Phase 1/Phase 2
Terminated NCT02601209 - Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Phase 1/Phase 2
Recruiting NCT05633381 - Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Phase 2/Phase 3
Active, not recruiting NCT04200443 - Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Phase 2
Recruiting NCT05711615 - Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Phase 1
Withdrawn NCT05174455 - Niraparib for the Treatment of Leiomyosarcoma Phase 2
Active, not recruiting NCT02428192 - Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Phase 2